The IMPACT study focused on screening men having BRCA1 and BRCA2 mutations for the diagnosis of PCa and revealed that the value of prostate-specific antigen (PSA) levels higher than 3.0 ng/mL and of prostate biopsy was greater in the BRCA2-mutated population than in the BRCA2 wild type [41]. The gene discussed is BRCA1; the disease is posterior cortical atrophy.